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heart reduction dose when comparing ABC to FB. Analysis was 
performed with BIOPLAN (BiOlogical evaluation of PLANs) PC 
based user-friendly software (evaluation of Dmax, Dmin, 
Dmean) and home-made Planning Reporting Orienteering 
(PRO)-DVH software. PRODVH produced Bio-DVH (Equivalent 
Dose Volume histograms for 25 fractions) that allowed the 
comparison regardless of the treatment schedule and that 
were used to calculate the average DVH for each set up. 
Secondary endpoints included dose reduction to the lung and 
procedural success rate. 
 
Results: Between May 2012 to February 2015, 50 patients 
with LBC are selected for receiving RT using ABC after both 
FB and ABC simulation. Procedural success was good, all 
patients have sufficient compliance and are been selected for 
this procedure. The primary endpoint was achieved: use of 
ABC reduced LAD/heart exposition (p < 0.01 T-student test). 
There was no significant difference between the free-
breathing and moderate deep inspiration breath-holding in 
the target volume coverage. The volume of the ipsilateral 
lung in the free-breathing technique was smaller than the 
moderate deep inspiration breath-holding techniques. All 
these data were confirmed with both software. 
 
Conclusion: ABC was well tolerated and significantly reduced 
heart/LAD dose without impairment in target volume 
coverage. No difference was find in lung dose reduction. Use 
of the ABC device during RT should be considered to reduce 
the risk of ischemic heart disease in populations at risk. 
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Purpose or Objective: Proper multi-atlas automated 
delineation can streamline clinical routine only when the 
proposed volume determination reasonably approximates the 
manual delineation. In this investigation we aimed to 
evaluate the automatic atlas-based segmentation of 
supraclavicular and level 3 lymph nodes for loco-regional 
irradiation of breast cancer. Further analysis were performed 
on the final plan’s dose coverage to the automated clinical 
target volume. 
 
Material and Methods: Between June and September 2015 
five consecutive breast cancer patients with clinical 
indication for loco-regional irradiation were selected. Pre-
defined breast delineation atlas of Mirada RTx (version 1.6.2, 
Mirada Medical, Oxford, United Kingdom) software were used 
to generate automated clinical target volumes (CTVauto) 
including the supraclavicular and the axillary level 3 lymph 
nodes. Responsible radiation oncologist delineated the 
reference CTV (CTVref) for each individual patients as well. 
Comparison metrics of Dice similarity (DI) and commonly 
contoured volume (CCV) were used. Furthermore the 
CTVauto was expanded with 1,2,3,4 and 5 mm uniform 
margin consecutively followed by an evaluation of the 
volumetric coverage of CTVref. Finally clinical plans were 
created expanding CTVref with 5 mm uniform margin using 
either direct antero-posterior beam or multi-beam IMRT. 
Dose coverage of the 95% of prescribed dose (V95) were 
compared for both CTVs. 
 
Results: The average CTVref was 35.1 cc (Standard deviation 
= 10.2), while for the CTVauto 42.1 cc (SD = 12.1). Mean DI 
and CCV were 0.73 (SD: 0.26) and 0.72 (SD: 0.28) 
respectively. Expanding the CTVauto up to 5 mm in 1 mm 
increments covered the CTVref with 53.9%, 77.9%, 88.1%, 
90.9% , 92.7% and 95.7% respectively. (Figure 1). For two 
patients single direct ante-posterior (AP) beam were used for 
the loco-regional treatment, while for the other three cases 
6 beam IMRT were used. Average V95% dose coverage of 
CTVref was 98.5% (SD: 3.0) which lowered to 92.0% (SD: 9.1%) 
for CTVauto. For the two patient with single AP field the 
CTVref were 93.0% and 99.5%, which dropped to 79.8% and 
99.4% for CTVauto. The multi-beam IMRT cases showed 100%, 





Conclusion: CTV delineation using an atlas-based auto-
segmentation shows promising results even in a small 
complicated volume delineation such as the loco-regional 
lymph nodes of breast. Further improvement of the 
delineation accuracy is expected by adding more cases to the 
initial multi-atlas (with 3 provided cases). 
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Purpose or Objective: Locally advanced breast cancer 
(LABC), clinically classified as cT4, is mostly identified in 
elderly patients, typically featuring unfavorable prognosis. It 
is usually associated with ulceration, bleeding and local pain, 
with prolonged course. Radiation therapy (RT) shows an 
important role in local control and symptomatic control. 
Hypofractionation radiotherapy scheme, with a dose of 13 Gy 
in two fractions with an interval of 48 hours (also known as 
RT-FLASH), allows acceptable results. With this study we aim 
to evaluate the response of the patients treated with RT-
FLASH. 
 
Material and Methods: LABC patients treated from 2001 to 
2015 with RT-FLASH were retrospectively included. Local 
response was clinically assessed. Kaplan-Meier method was 
used for locoregional progression-free survival (LPFS) and 
overall survival (OS) analysis. Type I error of 0.05. 
 
Results: 63 patients were included, with a median age of 78 
years (39-92 years), 61.9% with Karnofsky ≤80% and median 
progression time of 13.5 months (2-180 months). Carcinoma 
not otherwise specified (NOS) was the most common 
histological type (84.1%), with estrogen receptor-positive in 
71.4%. Most of the tumors were cT4b (50.8%) and cT4c 
(36.5%) with cN+ in 60.3% and cM1 in 44.4%. At the initial 
evaluation 46.0% had bleeding injuries. Two RT-FLASH were 
performed in 65.1% of the patients. During treatment there 
was no record of toxicity. There was reduction of bleeding 
(81.5%), size (69.8%) and ulceration (39.6%). Surgical 
conditions were acquired in 23.8% of the patients. Patients 
cM1 received chemotherapy more often than cM0 (57.7% vs. 
17.6%; p=0.001). Of the 63.9% patients that received 
hormone therapy (HT), 77.5% had 2 RT-FLASH (p=0.002 vs. 
non-HT), with a greater dimensional reduction in patients 
undergoing HT (81.1% vs 43, 8%, p = 0.010). LPFS at 2 and 5 
years was 76.6% and 66.1%, respectively. The 2-year OS was 
39.7% and 5-year OS was 19.5%, higher in cM0 patients 
(p<0.001), patients subjected to 2 RT- FLASH (p=0.003), or 
under HT (p=0.001). Multivariate analysis showed significant 
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impact of HT and cM1 (p=0.018 with HR =0.593 and p=0.006 
with HR=2.574, respectively). In the multivariate analysis of 
LPFS, HT and 2 RT-FLASH had prognostic impact (p=0.039 
with HR=0.297 and p=0.036 with HR=0.257, respectively). 
 
Conclusion: In the context of LABC, with poor prognosis, RT-
FLASH improves the quality of life, without registration of 
acute toxicity, and with reasonable OS. HT and the absence 
of metastasis at diagnosis had a positive impact on prognosis, 
significantly. LPFS was significantly higher in patients who 
underwent two RT-FLASH or HT. 
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Purpose or Objective: The increase in the local control and 
survival of breast cancer patients with postoperative 
radiotherapy(RT) has been demonstrated by many of 
randomized trials and metaanalysis. Because of this longer 
life expectancy; quality of life and minimizing of treatment 
toxicity have gained importance. More homogenous dose 
distribution in the treatment field and reduction of side 
effects is possible with new RT techniques. The aims of our 
study are to evaluate acute/subacute pulmonary effects and 
their differences with different RT modalities of 
postoperative breast RT via pulmonary function tests (PFT) 
and single photon emission computer tomography (SPECT) 
based lung perfusion scintigraphy (SLPS), and to exhibit 
optimum lung dose constraints data for breast cancer RT. 
Additionally this study enables to detect early pulmonary 
toxicity in the asymptomatic period and to treat it, if 
necessary. 
 
Material and Methods: In our study, voluntary breast cancer 
patients eligible for postoperative RT, who completed 
adjuvant systemic chemotherapy were separated equally into 
two groups of different RT techniques [3D conformal RT (3D-
CRT) and intensity-modulated radiotherapy (IMRT)]. To assess 
the acute/subacute pulmonary toxicity, we performed PFT 
and SLPS just before RT (baseline) and after 3 months of RT 
(control). After 1 month of RT patients were rechecked with 
only PFT. We assessed the relation between dosimetric data 




Figure 1: Fusion of single photon emission computer 
tomography (SPECT) based lung perfusion scintigraphy (SLPS) 
images and radiotherapy plans via VelocityAI® programme 
 
Results: Mean lung doses and lung volumes receiving ≤20Gy 
(V1, V5, V10, V20) were significantly higher in IMRT group 
(p<0.001) (Figure 2). There was no significant difference in 
PFT changes after RT between the two RT techniques 
(p>0.05). Higher lung doses (p<0.001) and more significant 
mean reduction of scintigraphic uptake were observed in low 
dose volumes with IMRT (p<0.05). In 3D-CRT group, the mean 
reduction of scintigraphic uptake was higher in the lobe, that 
receives the highest mean dose (ipsilateral lobe) (p<0.05). 
Furthermore, even though right supraclavicular area, which 
effects the upper lung zone was irradiated, frequently the 
right middle lobe received more radiation, not right upper 
lobe. Eventually, none of the patients had grade ≥2 LENT -
SOMA lung toxicity. We didn’t find any relationship between 
patient characteristics (smoking history, age, chemotherapy 
type, surgery type, tumor location, RT field and technique) 
and radiation induced pulmonary toxicity. 
   
 
 
Figure 2: Bilateral lung, ipsilateral lung ve ipsilateral lung 
lobe mean V1, V5, V10, V20, V30, V40, V50 values 
 
Conclusion: We found that V20 volume of lung is a similar 
parameter for evaluation of different breast RT techniques 
and evaluation of low and high dose volumes can be more 
feasible. Larger group of patients and longer follow-up can 
lead to more significant results.  
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Purpose or Objective: Cardiac dose delivered during 
tangential radiotherapy is increasingly scrutinized, but the 
cardiac dose delivered during electron boost is not routinely 
calculated. We retrospectively reviewed cases in which an 
electron boost was employed to deliver a phase 2 to a tumour 
bed (TB) overlying the heart to establish the proportion of 
cases and type of cases in which this treatment delivered a 
significant cardiac dose.  
 
Material and Methods: A cohort of left sided breast cancer 
cases receiving radiotherapy in a single treatment centre 
over a 4 month period were reviewed. Those patients 
receiving a phase 2 electron boost to a TB in the mid/ lower 
part of the left breast were identified. For those in which an 
electron beam was incident on the heart, fully commissioned 
Monte Carlo dose calculation was used to derive the dose 
delivered to whole heart and left anterior descending artery 
assuming a boost dose of 16Gy in 8 fractions to the 100%. 
 
Results: A total of 24 patients received a boost to a TB in the 
mid/ lower part of the left breast. Of these, 15 were treated 
with an electron beam incident on the heart. In 6/15 (40%) 
the mean heart dose delivered by the boost component was 
0.5Gy. The maximum mean heart dose was 1.02Gy. In all 6 
cases, the energy employed was >9MeV. 
 
Conclusion: The heart dose delivered by an electron boost 
with beam incident on the heart can be significant, especially 
if an energy >9MeV is employed. In such cases, mini-
tangential treatment in deep inspiratory breath hold is 
recommended. 
